Reuters broke the news that an estimated 30 million to 50 million doses of Johnson & Johnson’s COVID-19 vaccine made earlier this year sit idle in Emergent BioSolutions Inc’s plant in Baltimore, awaiting a green light from U.S. regulators to ship. A source said Emergent is waiting for the U.S. Food and Drug Administration to approve release of those doses. Emergent shares opened nearly 1% higher following the Reuters report.
Health
Reuters reveals Tens of millions of J&J COVID-19 shots sit at Baltimore factory
28 October 2021, 11:28 am 1 minute
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Business & Finance
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text